Evidence map›Paper›PMID 36814255›Full record

ArticleOrphanet journal of rare diseases2023

Post-acute phase and sequelae management of epidermal necrolysis: an international, multidisciplinary DELPHI-based consensus.

S Ingen-Housz-Oro, V Schmidt, M M Ameri, R Abe, A Brassard, A Mostaghimi, A S Paller, A Romano, B Didona, B H Kaffenberger and 50 more

Open access · goldAbstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Orphanet journal of rare diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Challenges in Diagnosing and Treatment of Pediatric Necrotic Skin Conditions: A Retrospective Study.Medical science monitor : international medical journal of experimental and clinical research · 2025
    Article
  5. Article
  6. Review
  7. Severe cutaneous adverse reactions.Nature reviews. Disease primers · 2024
    Review
  8. Review
  9. Toxic epidermal necrolysis - clinicopathological aspects and therapeutic management.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

60 authors at 20 institutions in 19 countries.

S Ingen-Housz-Oro *Department of Dermatology, AP-HP, Henri Mondor Hospital, 1 Rue Gustave Eiffel, 94000, Créteil, France. saskia.oro@aphp.fr.ORCID 0000-0002-5383-7096
V Schmidt *University Hospital Basel, Basel, Switzerland.
M M AmeriFaculty of Medicine, University of Zurich, Zurich, Switzerland. saskia.oro@aphp.fr.
R AbeDivision of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
A BrassardDepartment of Dermatology, UC Davis Medical Center, Sacramento, CA, USA.
A MostaghimiDepartment of Dermatology, Brigham and Women's Hospital, Boston, MA, USA.
A S PallerDepartment of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
A RomanoOasi Research Institute-IRCCS, Troina, Italy.
B DidonaToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France.
B H KaffenbergerToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France.
B Ben SaidToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France.
B Y H ThongDepartment of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore, Singapore.
B RamsayDepartment of Dermatology, University Hospital Limerick, Limerick, Ireland.
E BrezinovaToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France.
B MilpiedToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France.
C G MortzDepartment of Dermatology and Allergy Center, Odense Research Center for Anaphylaxis (ORCA), Odense University Hospital, Odense, Denmark.
C Y ChuDepartment of Dermatology, National Taiwan University Hospital, National Taiwan University College of Medicine, No. 7, Chung-Shan South Road, Taipei, 10002, Taiwan.
C SotozonoDepartment of Ophthalmology, Kyoto Prefectural University of Medicine, 465 Kajii-Cho, Hirokoji-Agaru, Kawaramach-Dori, Kamigyo-Ku, Kyoto, 602-0841, Japan.
J GueudryReference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France.
D G FortuneDepartment of Psychology, University of Limerick, Limerick, Ireland.
S M DridiReference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France.
D TartarDepartment of Dermatology, University of California Davis, Sacramento, CA, USA.
G Do-PhamReference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France.
E GabisonFondation Ophtalmologique Adolphe de Rothschild, Paris, France.
E J PhillipsInstitute for Immunology and Infectious Diseases, Murdoch University, Murdoch, WA, Australia.
F LewisSt John's Institute of Dermatology, Guy's and St Thomas' Hospital, London, UK.
C SalavastruToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France.
B HorvathToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France.
J DartMoorfields Eye Hospital NHS Foundation Trust, The UCL Institute of Ophthalmology, London, UK.
J SetterfieldToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France.
J NewmanDepartment of Dermatology, King's College Hospital NHS Foundation Trust, London, UK.
J T SchulzDivision of Burns, Massachusetts General Hospital, Boston, 02114, USA.
A DelcampeReference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France.
K BrockowDepartment of Dermatology and Allergy Biederstein, School of Medicine, Technical University of Munich, Munich, Germany.
L Seminario-VidalDepartment of Dermatology and Cutaneous Surgery, University of South Florida, Tampa, FL, USA.
L JörgDepartment of Dermatology, University Hospital Zurich, Zurich, Switzerland.
M P WatsonCornea and External Eye Disease Service, Moorfields Eye Hospital, London, UK.
M GonçaloDepartment of Dermatology, Coimbra University Hospital Center, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.
M LucasMedical School, University of Western Australia, Perth, WA, 6009, Australia.
M TorresAllergy Unit, IBIMA-Regional University Hospital of Malaga-UMA, Málaga, Spain.
M H NoeDepartment of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
N HamaDivision of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
N H ShearDepartment of Dermatology, University of Toronto, Toronto, ON, Canada.
P O'ReillyDepartment of Nursing and Midwifery, University of Limerick, Limerick, Ireland.
P WolkensteinDepartment of Dermatology, AP-HP, Henri Mondor Hospital, 1 Rue Gustave Eiffel, 94000, Créteil, France.
P RomanelliDr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami, Miller School of Medicine, Miami, FL, USA.
R P Dodiuk-GadDermatology Department, Emek Medical Center, Bruce Rappaport Faculty of Medicine, Technion - Institute of Technology, Haifa, Israel.
R G MichelettiDepartment of Dermatology and Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
G S TiplicaToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France.
R SheridanBurn Service, Boston Shriners Hospital for Children, Boston, MA, USA.
S RauzAcademic Unit of Ophthalmology, Birmingham and Midland Eye Centre, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.
S AhmadMoorfields Eye Hospital NHS Foundation Trust, The UCL Institute of Ophthalmology, London, UK.
S L ChuaToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France.
T H FlynnOphthalmology, Bon Secours Hospital, Cork, Ireland.
W PichlerADR-AC GmbH, Bern, Switzerland.
S T LeDepartment of Dermatology, UC Davis Medical Center, Sacramento, CA, USA.
E MaverakisDepartment of Dermatology, UC Davis Medical Center, Sacramento, CA, USA.
S WalshToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France.
L E French *ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France.
M C BrüggenToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France.
University of California Davis Medical Center · USUniversity of Zurich · CHBrigham and Women's Hospital · USCarol Davila University of Medicine and Pharmacy · ROKing's College Hospital NHS Foundation Trust · GBMoorfields Eye Hospital NHS Foundation Trust · GBNiigata University · JPUniversity of Limerick · IEUniversity of Miami · USADR-AC (Switzerland) · CHAssistance Publique – Hôpitaux de Paris · FRBirmingham and Midland Eye Centre · GBBon Secours Hospital Cork · IEEuropean Clinical Research Infrastructure Network · FRFondation Ophtalmologique Adolphe de Rothschild · FRGuy's and St Thomas' NHS Foundation Trust · GBHarvard University · USHôpital Charles-Nicolle · FRHôpital Edouard Herriot · FRHôpital Intercommunal de Créteil · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLong-term sequelae are frequent and often disabling after epidermal necrolysis (Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)). However, consensus on the modalities of management of these sequelae is lacking.

objectivesWe conducted an international multicentric DELPHI exercise to establish a multidisciplinary expert consensus to standardize recommendations regarding management of SJS/TEN sequelae.

methodsParticipants were sent a survey via the online tool "Survey Monkey" consisting of 54 statements organized into 8 topics: general recommendations, professionals involved, skin, oral mucosa and teeth, eyes, genital area, mental health, and allergy workup. Participants evaluated the level of appropriateness of each statement on a scale of 1 (extremely inappropriate) to 9 (extremely appropriate). Results were analyzed according to the RAND/UCLA Appropriateness Method.

resultsFifty-two healthcare professionals participated. After the first round, a consensus was obtained for 100% of 54 initially proposed statements (disagreement index < 1). Among them, 50 statements were agreed upon as 'appropriate'; four statements were considered 'uncertain', and ultimately finally discarded.

conclusionsOur DELPHI-based expert consensus should help guide physicians in conducting a prolonged multidisciplinary follow-up of sequelae in SJS-TEN.

Indexed as

Stevens-Johnson SyndromeDisease ProgressionHumansSkinConsensusDelphiEpidermal necrolysisQuality of lifeSequelaeStevens-Johnson syndromeToxic epidermal necrolysis

Identifiers

PMID36814255
PMCPMC9945700
OpenAlexW4321499575

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.